阻碍神经退行性疾病的发展:蓝藻细菌可能是治疗的新方法吗?
Vitória Ramos1, Mariana Reis2, Leonor Ferreira2,3
1School of Health, Polytechnic Institute of Porto (ESS/P.PORTO), Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal.
Biomolecules
|October 28, 2023
概括
菌化合物通过提供抗氧化和抗炎作用,显示出治疗神经退行性疾病 (NDs) 的前景. 这篇评论探讨了它们对阿尔茨海默氏症等疾病的潜在神经保护性质.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 神经退行性疾病 (NDs) 涉及渐进的神经元损失和复杂的病理,如蛋白质聚合,炎症和氧化应激.
- 目前对阿尔茨海默病 (AD),帕金森病 (PD),多发性硬化症 (MS),ALS和亨廷顿病 (HD) 等ND的治疗方法仅仅是治疗症状,而不是治愈疾病.
- 迫切需要新的治疗点和药物,推动了对替代治疗策略的研究.
研究的目的:
- 审查主要神经退行性疾病 (NDs) 的病理生理学.
- 突出从蓝藻细菌衍生的化合物的神经保护潜力.
- 总结蓝菌化合物对抗神经退行症的有益作用.
主要方法:
- 关于神经退行性疾病和蓝菌的科学文章的文献评论.
- 对涉及NDs的生物化学途径的分析.
- 检查详细介绍蓝菌化合物的药理性质的研究.
主要成果:
- 菌产生各种各样的化合物,具有显著的抗炎,抗氧化,免疫调节和神经保护作用.
- 这些化合物针对ND的关键病理机制,包括氧化应激和炎症.
- 有证据表明,蓝藻细菌衍生的分子可以减轻神经元损伤和功能障碍.
结论:
- 蓝菌化合物代表了开发新治疗药物治疗神经退行性疾病的有希望的来源.
- 对这些天然产品的进一步研究可能会导致对目前无法治愈的NDS的新药发现.
- 用蓝菌化合物向炎症和氧化应激提供了一个可行的神经保护策略.
相关概念视频
01:30Bacterial Phylum Cyanobacteria
27
Cyanobacteria are a diverse group of oxygenic, phototrophic bacteria that played a pivotal role in converting Earth’s atmosphere from anoxic to oxygen-rich billions of years ago. They exhibit remarkable morphological diversity, ranging from unicellular forms to filamentous types, with cell sizes varying between 0.5 μm and 100 μm. Cyanobacteria are classified into five groups: Chroococcales (unicellular, dividing by binary fission), Pleurocapsales (unicellular, dividing by...
27
01:29Microorganisms in Medicine and Therapeutics
35
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
35
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
00:46Bioremediation
18.7K
Bioremediation is the use of prokaryotes, fungi, or plants to remove pollutants from the environment. This process has been used to remove harmful toxins in groundwater as a byproduct of agricultural run-off and also to clean up oil spills.
18.7K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131
01:15Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567